Open-access Effect of mirtazapine on TNF-Α and IL-6 gene expression in peripheral blood mononuclear cells from healthy cats

[Efeito da mirtazapina na expressão de TNF-Α e IL-6 em células sanguíneas mononucleares periféricas de gatos saudáveis]

ABSTRACT

Mirtazapine, a tetracyclic antidepressant initially developed for human use, has been widely used in feline medicine due to its anxiolytic, antiemetic, and appetite stimulant properties. Some psychotropic medications have been shown to modulate immune activation, but the effects of mirtazapine on the cat’s immune system remain unclear. This study aimed to evaluate the in vitro effects of mirtazapine on gene expression of the proinflammatory cytokines TNF-α and IL-6 in peripheral blood mononuclear cells (PBMC) from healthy domestic cats. TNF-α and IL-6 are involved in the pathogenesis of inflammatory and infectious diseases affecting felines. For this purpose, PBMC from cats were treated overnight with 50 μM of mirtazapine, and the expression of these cytokines was analyzed by real-time PCR. There was a significant reduction in the expression of TNF-α and IL-6 in the treated cells compared to the control group, indicating an anti-inflammatory effect of mirtazapine. The anti-inflammatory effects of mirtazapine may represent a novel therapeutic option for cats with inflammatory conditions.

Keywords:
mirtazapine; cytokines; inflammation; antidepressant; immunomodulation

RESUMO

A mirtazapina, um antidepressivo tetracíclico inicialmente desenvolvido para uso humano, tem sido amplamente utilizada na medicina veterinária em felinos devido às suas propriedades estimulantes do apetite e antieméticas. Algumas medicações psicotrópicas têm demonstrado a indução de imunomodulação, mas os efeitos da mirtazapina no sistema imune de gatos ainda são desconhecidos. Este estudo teve como objetivo avaliar os efeitos in vitro da mirtazapina sobre a expressão gênica das citocinas pró-inflamatórias TNF-α e IL-6 em células mononucleares do sangue periférico (PBMC) de gatos saudáveis. TNF-α e IL-6 estão envolvidas na patogênese de doenças inflamatórias e infecciosas que afetam felinos. Para isso, PBMC de gatos foram tratadas overnight com mirtazapina a 50μM, e a expressão destas citocinas foi analisada por PCR em tempo real. Houve uma redução significativa na expressão de TNF-α e IL-6 nas células tratadas em comparação ao grupo controle, indicando um efeito anti-inflamatório da mirtazapina. Os efeitos anti-inflamatórios da mirtazapina podem representar uma nova opção terapêutica para gatos com condições inflamatórias.

Palavras-chave:
mirtazapina; felinos; citocinas; inflamação; antidepressivo

INTRODUCTION

Mirtazapine, originally developed as an antidepressant for human use, has gained recognition in veterinary medicine due to its pharmacological properties. It acts as an antagonist of serotonin 5-HT2 and 5-HT3 receptors while also functioning as an agonist of alpha-2 adrenergic receptors (Tazehkand and Topaktas, 2015). These mechanisms make mirtazapine useful for various animal therapeutic effects, such as stimulating appetite and antiemetic action (Quimby and Lunn, 2013). It is particularly beneficial in conditions like chronic renal failure, liver disease, and neoplasia (Quimby and Lunn, 2013; Almishri et al., 2019; Arrieta et al., 2024; Evoh et al., 2024). Mirtazapine has also been indicated as a behavioral and appetite modulator for anxious or stressed cats (Quimby and Lunn, 2013).

Mirtazapine, when used at therapeutic doses, has a favorable toxicity profile and is not genotoxic to lymphocytes (Tazehkand and Topaktas, 2015). Additionally, studies have indicated that mirtazapine can modify cytokine profiles and decrease inflammatory responses, in humans and mice (Gupta et al., 2016; Davis et al., 2020). The effects of mirtazapine on the immune system of cats remain to be elucidated.

Cytokines are proteins secreted by various cells in response to different stimuli. They play a crucial role in regulating immune and inflammatory responses through complex networks and serve as biomarkers for numerous diseases (Martins and Sacilotto, 2021). Depending on their functions, cytokines can be categorized as pro-inflammatory or anti-inflammatory. In cats, interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α are the main mediators of the acute phase inflammatory response (Paltrinieri, 2007). IL-6 and TNF-α, facilitate inflammatory reactions and tend to stimulate immuno-competent cells. However, when inflammation becomes uncontrolled or unresolved, it can lead to significant tissue damage. TNF-α is a cytokine secreted mainly by monocytes, macrophages, and lymphocytes. Its main functions are to promote inflammation by recruiting neutrophils and monocytes to the site of infection and induction of apoptosis in infected or tumor cells, acting directly in defense against pathogens (Webster and Vucic, 2020). However, in certain circumstances, TNF-α can contribute to increased inflammation, tissue damage, and even the development of tumors (Popa et al., 2007; Luo and Zheng, 2016; Peralta et al., 2023; Rodrigues-Jesus et al., 2024). Interleukin 6 (IL-6) is quickly produced in response to infections and tissue injuries, playing a crucial role in host defense by stimulating acute phase responses, hematopoiesis, and immune reactions. Chronic inflammatory and autoimmune diseases, as well as cancer development, are linked to high and persistent levels of IL-6, similar to TNF-α (Morrison, 2012; Tanaka et al., 2014; Luo and Zheng, 2016; Chen et al., 2022).

In cats, elevated levels of TNF-α and IL-6 have been observed in various conditions, including certain infectious diseases, chronic inflammatory diseases, some neoplasms, and situations associated with immunosuppression (Doki et al., 2013; Heilmann and Suchodolski., 2015; Malbon et al., 2019; Martins and Sacilotto, 2021; Villatoro et al., 2022). The present study aimed to evaluate the effects of mirtazapine in vitro on the gene expression of the cytokines TNF-α and IL-6 in the peripheral blood monocytes and lymphocytes of healthy cats.

This study is one of the first to investigate the in vitro effects of mirtazapine on the gene expression of the pro-inflammatory cytokines TNF-α and IL-6 in PBMC of healthy cats. By demonstrating that mirtazapine can modulate the expression of key cytokines involved in feline inflammatory responses, this study expands the current understanding of the drugs pharmacological profile beyond its conventional clinical indications. These findings provide a novel scientific basis for considering mirtazapine as a potential adjunctive therapeutic option for the management of inflammatory diseases in cats, thereby advancing knowledge in feline veterinary pharmacology and immunology.

ETHICAL ASPECTS

The research was submitted to the Ethics Committee on Animal Use of the Federal University of Pelotas and approved under the number 039127/2024-52.

MATERIALS AND METHODS

Mirtazapine (C17H19N3) was provided by Farmacia Vida Nova (Pelotas, Rio Grande do Sul, Brazil) in its pure form. The mirtazapine was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich Co., USA) to obtain a 0.1 M stock solution. The stock solution was fractionated and stored at -20 °C for later use.

Six healthy domestic cats, aged from four to six years, were selected for the obtention of peripheral blood mononuclear cells (PBMC). All cats were neutered, domiciled, and had an ideal body condition score. All cats tested negative for feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) using the SensPERT FELVⓇ Ag/FIV Ab Test Kit (Dechra Pharmaceuticals, Londrina, Paraná, Brazil).

PBMC were obtained by collecting 3 mL of blood from the cephalic vein of each cat into EDTA-containing tubes. PBMC were isolated from a pooled sample using Ficoll-Hypaque density gradient centrifugation (Histopaque, Sigma-Aldrich Co., St. Louis, MO, USA). The blood sample, diluted 1:2 in cell culture medium, was carefully layered over 6 mL of Ficoll-Hypaque solution in a 15 mL conical tube and centrifuged at 340 × g for 25 minutes at 20 °C. The upper layer containing plasma and platelets was removed using a sterile pipette, and the mononuclear cell layer at the interface was collected. PBMC was washed once with phosphate-buffered saline (PBS), followed by centrifugation at 340 × g for 10 minutes at 20 °C to remove residual Ficoll-Hypaque and other contaminants. Residual erythrocytes were eliminated using a lysis buffer (0.16 M NH₄Cl; 0.17 M Tris, pH 7.2) for five minutes with gentle agitation. Then, PBMC were counted and assessed for viability using a Fuchs-Rosenthal chamber and trypan blue exclusion dye. The cells were used immediately for in vitro stimulation studies.

The cytotoxicity of mirtazapine was assessed in PBMCs after 24 hours of treatment, using the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction method, as described by Mosmann (1983). The non-cytotoxic concentration established for the experiment was 50µM.

PBMC were cultivated in Eagles minimum essential medium (E-MEM, Sigma Aldrich, St. Louis, Missouri, USA) supplemented with 10% of bovine fetal serum (Gibco, Waltham, Massachusetts, USA), penicillin (Sigma-Aldrich, St. Louis, Missouri, USA), streptomycin (Vetec, Duque de Caxias, Rio de Janeiro, Brazil), amphotericin B (Cristália, Itapira, São Paulo, Brazil) and enrofloxacin (Bayer, São Paulo, São Paulo, Brazil). PBMC were adjusted to a concentration of 105 cells/well in 100µL of E-MEM. PBMCs were incubated overnight with 50µM mirtazapine (treated group) or culture medium alone (control group) at 37°C in a humidified 5% CO₂ atmosphere. After incubation, the cells were collected in 1 mL of TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and stored at −80°C until RNA extraction.

Total RNA was extracted from PBMC using TRIzol (Invitrogen, Carlsbad, California, USA), according to the manufacturers protocol. The purity, quantity, and integrity of the isolated RNA were assessed using a NanoDrop™ Lite Spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The A260:A280 ratio ranged from 1,8 to 2,0. cDNA was synthesized from 10ng/μL of total RNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, Massachusetts, USA), following the manufacturer’s instructions.

Sample testing was performed in triplicate using the StepOnePlus™ Real-Time PCR System (Applied Biosystems™) thermocycler. To evaluate the expression of pro-inflammatory cytokines TNFα and IL-6, PCR reaction with SYBR Green GoTaq® qPCR Master Mix (Promega, Madison, Wisconsin, USA) was performed according to the manufacturer.

Gliceraldeído-3-Fosfato Desidrogenase (GAPDH) and β-actin were used for the normalization of gene expression, which was determined using the 2−ΔΔCt method. The selected primers are described in Tab.1. The thermocycling conditions for amplification of the genetic material consisted of an initial denaturation step for 10 minutes at 95ºC, 40 cycles of 15 seconds at 95ºC and 1 minute at 60ºC, and the dissociation curve with 95ºC for 15 seconds, 55ºC for 1 minute, and 95ºC for 15 seconds.

The fold change of mRNA was calculated by the ΔΔCT method (Livak and Schmittgen, 2001). Data were subjected to analysis of variance (ANOVA) followed by Tukeys post hoc test. Statistically significant differences were considered when p<0.05 for multiple comparisons. Analyses were performed using GraphPad Prism version 7 (GraphPad Software Inc., La Jolla, CA, USA).

Table 1
Nucleotide sequences of primers used for real-time PCR analysis

RESULTS

Although mirtazapine is widely used in veterinary medicine for its appetite-stimulating, antiemetic, and anxiolytic properties, its effects on the immune system in felines have not yet been explored at the molecular level. Thus, the present study represents a pioneering investigation into the effect of mirtazapine on the gene expression of important pro-inflammatory cytokines in cats.

PBMC are frequently used to evaluate the impact of different treatments on immune cell function because they reflect the physiological immune response in vivo. PBMC contains a mix of lymphocytes, monocytes, and dendritic cells, which play crucial roles in cytokine production. In this study, PBMC obtained from healthy cats were treated with 50µM mirtazapine overnight. Treated PBMC exhibited a significant reduction in gene expression of the pro-inflammatory cytokines TNF-α and IL-6 compared to untreated cells, as shown in Fig. 1.

Figure. 1
(A) TNF-α gene expression in peripheral blood mononuclear cells of healthy cats treated with 50µM mirtazapine overnight. (B) Interleukin-6 gene expression in peripheral blood mononuclear cells of healthy cats treated with 50µM mirtazapine overnight. P<0.001. CC - cells without mirtazapine; CM - cell with mirtazapine). Data represent mean ±S.E.M. (n=3).

DISCUSSION

The anti-inflammatory effect of mirtazapine observed in this study aligns with findings from similar studies conducted on other species. In a murine model, a reduction in the levels of several pro-inflammatory cytokines, including TNF-α and IL-6, is observed in situations of stress and experimentally induced systemic inflammation (Pu et al., 2022). In the study by Fang et al. (2012), the treatment of mice with mirtazapine, in addition to being effective in attenuating systemic inflammation, reducing the secretion of TNF-α and IL-6, showed the capacity to significantly reduce tumor growth.

In humans, the effect of mirtazapine on the immune system has been studied mainly in the context of major depressive disorder, since immune dysregulation caused by chronic stress is present in most patients. This dysregulation is associated with the occurrence of low-grade inflammation, characterized by an increase in the level of pro-inflammatory molecules, such as C-reactive proteins and cytokines, including TNF-α and IL-6 (Arteaga-Henríquez et al., 2019). Under these conditions, mirtazapine has been shown to reduce the levels of pro-inflammatory cytokines, suggesting an immunomodulatory effect complementary to its antidepressant mechanism (Alikhan et al., 2013; Eskeland et al., 2017). Furthermore, the use of some cytokines as immunological markers to predict the efficacy of treatment with antidepressants (including tetracyclics, which include mirtazapine) has been described, with patients who present a reduction in baseline levels of IL-6 predicting a better response to treatment (Lee and Giuliani, 2019).

IL-6 acts as a critical factor in the progression and therapy of several types of cancer. The increased expression of IL-6 may act as an oncogene, potentially influencing tumor growth and spread (Lee and Giuliani, 2019). In feline and human oral squamous cell carcinoma, for example, elevated IL-6 levels have been associated with poorer prognosis and shorter survival times (Dineshkumar et al., 2016; Adachi et al., 2024).

From a clinical perspective, the mirtazapine-induced reduction in TNF-α and IL-6 expression in cats is particularly promising. Cats with certain relatively common and debilitating diseases, such as sporotrichosis, calicivirus infection, chronic gingivostomatitis, and feline infectious peritonitis exhibit a sustained systemic inflammatory state in which TNF-α and IL-6 play a critical role (Luo and Zheng, 2016; Sekiguchi et al., 2021; Peralta et al., 2023). Similarly, the inflammatory reaction present in different types of feline lesions is associated with the development of more aggressive tumors (Rodrigues-Jesus et al., 2024).

High levels of IL-6 are also associated with anorexia, weight loss, fatigue, and poor prognosis in critical illness (Hunter and Jones, 2015). The ability of mirtazapine to modulate IL-6 expression may therefore contribute not only to the reduction of inflammation but also to the indirect improvement of nutritional status and quality of life in these patients.

Although the precise mechanisms by which mirtazapine reduces the expression of TNF-α and IL-6 are not completely understood, it can be speculated that its effect is related to the interaction with serotonergic receptors, the activation of pattern recognition receptors (PRR) and/or the regulation of inflammatory intracellular signaling pathways, such as the NF-κB and JAK/STAT intracellular signaling pathways involved in cytokine production (Webster and Vucic, 2020; Martins and Sacilotto, 2021; Aliyu et al., 2022). Future evaluation of other inflammatory mediators and molecular pathways associated with mirtazapine use may provide more details about these mechanisms.

It is crucial to evaluate whether the reduction in TNF-α and IL-6 expression caused by mirtazapine is sustained over prolonged use. In this study, the anti-inflammatory effect of mirtazapine was observed after a single exposure to PBMC. Research shows that repeated administration of mirtazapine in humans may decrease the production of pro-inflammatory cytokines (Alikhan et al., 2013). Additionally, future studies should investigate the systemic effects of this drug in greater detail to enhance its applicability and safety, as well as optimize treatment for cats affected by inflammatory diseases.

CONCLUSIONS

The discovery of mirtazapine anti-inflammatory properties expands its therapeutic potential in feline medicine. This finding suggests the drug is a promising alternative for managing diseases that affect cats caused by imbalances in pro-inflammatory cytokines.

ACKNOWLEDGMENTS

We gratefully acknowledge the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil, for providing the research scholarship.

REFERENCES

  • ACHLEITNER, A.; CLARK, M.E.; BIENZLE, D. T-regulatory cells infected with feline immunodeficiency virus up-regulate programmed death-1 (PD-1). Vet. Immunol. Immunopathol., v.143, p.307-313, 2011.
  • ADACHI, T.; GODA, H.; SHINRIKI, S. et al Prognostic significance of serum interleukin-6 levels in oral squamous cell carcinoma. Cureus, v.16, p.e54439, 2024.
  • ALIKHAN, S.M.; LEE, J.A.; DRATCU, L. Mirtazapine treatment of a severe depressive episode and resolution of elevated inflammatory markers. Case Rep. Psychiatry, v.2013, p.1-3, 2013.
  • ALIYU, M.; ZOHORA, F.T.; ANKA, A.U. et al Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach. Int. Immunopharmacol., v.111, p.e109130, 2022.
  • ALMISHRI, W.; SHAHEEN, A.A.; SHARKEY, K.A.; SWAIN, M.G. The antidepressant mirtazapine inhibits hepatic innate immune networks to attenuate immune-mediated liver injury in mice. Front. Immunol, v.10, p.803, 2019.
  • ARRIETA, O.; CÁRDENAS-FERNÁNDEZ, D.; RODRIGUEZ-MAYORAL, O. et al Mirtazapine as appetite stimulant in patients with non-small cell lung cancer and anorexia: a randomized clinical trial. JAMA Oncol, v.10, p.305, 2024.
  • ARTEAGA-HENRÍQUEZ, G.; SIMON, M.S.; BURGER, B. et al Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME Consortium. Front. Psychiatry, v.10, p.458, 2019.
  • CHEN, J.; WEI, Y.; YANG, W. et al IL-6: the link between inflammation, immunity and breast cancer. Front. Oncol., v.12, p.903800, 2022.
  • DAVIS, R.P.; ALMISHRI, W.; JENNE, C.N.; SWAIN, M.G. The antidepressant mirtazapine activates hepatic macrophages, facilitating pathogen clearance while limiting tissue damage in mice. Front. Immunol, v.11, p.578654, 2020.
  • DINESHKUMAR, T.; ASHWINI, B.K.; RAMESHKUMAR, A. et al Salivary and serum interleukin-6 levels in oral premalignant disorders and squamous cell carcinoma: diagnostic value and clinicopathologic correlations. Asian Pac. J. Cancer Prev, v.17, p.4899-4906, 2016.
  • DOKI, T.; TAKANO, T.; NISHIYAMA, Y.; NAKAMURA, M.; HOHDATSU, T. Generation, characterization and therapeutic potential of anti-feline TNF-alpha MAbs for feline infectious peritonitis. Res. Vet. Sci., v.95, p.1248-1254, 2013.
  • ESKELAND, S.; HALVORSEN, J.; TANUM, L. Antidepressants have anti-inflammatory effects that may be relevant to dermatology: a systematic review. Acta Derm. Venerol, v.97, p.897-905, 2017.
  • EVOH, O.V.; CHATTERJEE, T.; RAJI, M.; O’MAHONY, S. Mirtazapine: a one-drug intervention for the physical and psychological symptoms of end-stage renal disease (ESRD). Cureus, v.16, p.e71439, 2024.
  • FANG, C.K.; CHEN, H.W.; CHIANG, I.T. et al Mirtazapine inhibits tumor growth via immune response and serotonergic system. PLoS One, v.7, p.e38886, 2012.
  • GUPTA, R.; GUPTA, K.; TRIPATHI, A.K. et al Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-α in patients of major depressive disorder with severe depression. Pharmacology, v.97, p.184-188, 2016.
  • HEILMANN, R.M.; SUCHODOLSKI, J.S. Is inflammatory bowel disease in dogs and cats associated with a Th1 or Th2 polarization? Vet. Immunol. Immunopathol, v.168, p.131-134, 2015.
  • HUNTER, C.A.; JONES, S.A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol., v.16, p.448-457, 2015.
  • KHAIR, M.H.; SELVARAJAH, G.T.; OMAR, A.R.; MUSTAFFA-KAMAL, F. Expression of Toll-like receptors 3, 7, 9 and cytokines in feline infectious peritonitis virus-infected CRFK cells and feline peripheral monocytes. J. Vet. Sci, v.23, p.e27, 2022.
  • KIPAR, A.; LEUTENEGGER, C.M.; HETZEL, U. et al Cytokine mRNA levels in isolated feline monocytes. Vet. Immunol. Immunopathol., v.78, p.305-315, 2001.
  • LEE, C.H.; GIULIANI, F. The role of inflammation in depression and fatigue. Front. Immunol., v.10, p.1696, 2019.
  • LIVAK, K.J.; SCHMITTGEN, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT. Methods, v.25, p.402-408, 2001.
  • LUO, Y.; ZHENG, S.G. Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms. Front. Immunol, v.7, p.604, 2016.
  • MALBON, A.J.; FONFARA, S.; MELI, M.L. et al Feline infectious peritonitis as a systemic inflammatory disease: contribution of liver and heart to the pathogenesis. Viruses, v.11, p.1144, 2019.
  • MARTINS, L.V.O.; SACILOTTO, N.C. Interleucina-6. Rev. Paulista Reumatol., v.3, p.12-21, 2021.
  • MORRISON, W.B. Inflammation and cancer: a comparative view. Vet. Intern. Med, v.26, p.18-31, 2012.
  • MOSMANN, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, v.65, p.55-63, 1983.
  • PALTRINIERI, S. The feline acute phase reaction. Vet. J, v.177, p.26-35, 2007.
  • PERALTA, S.; GRENIER, J.K.; WEBB, S.M. et al Transcriptomic signatures of feline chronic gingivostomatitis are influenced by upregulated IL6. Res. Sq., v.13, p.e14437, 2023.
  • POPA, C.; NETEA, M.G.; VAN RIEL, P.L. et al The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res., v.48, p.751-762, 2007.
  • PU, Y.; ZHAO, L.; XI, Y. et al The protective effects of Mirtazapine against lipopolysaccharide (LPS)-induced brain vascular hyperpermeability. Bioengineered, v.13, p.3680-3693, 2022.
  • QUIMBY, J.M.; LUNN, K.F. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet. J., v.197, p.651-655, 2013.
  • RODRIGUES-JESUS, J.; CANADAS-SOUSA, A.; OLIVEIRA, P. et al Distribution of inflammatory infiltrate in feline mammary lesions: relationship with clinicopathological features. Vet. Comp. Oncol., v.22, p.398-409, 2024.
  • SEKIGUCHI, K.; KOBA, R.; OKA, T.; TOHYA, Y. Caliciviruses induce mRNA of tumor necrosis factor α via their protease activity. Virus Res, v.306, p.e198595, 2021.
  • TANAKA, T.; NARAZAKI, M.; KISHIMOTO, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol., v.6, p.a016295, 2014.
  • TAZEHKAND, M.; TOPAKTAS, M. The in vitro genotoxic and cytotoxic effects of remeron on human peripheral blood lymphocytes. Drug Chem. Toxicol., v.38, p.266-271, 2015.
  • VILLATORO, A.J.; MARTÍN-ASTORGA, M.D.C.; Alcoholado, C. et al Secretory profile of adipose-tissue-derived mesenchymal stem cells from cats with calicivirus-positive severe chronic gingivostomatitis. Viruses, v.14, p.1146, 2022.
  • WEBSTER, J.D.; VUCIC, D. The balance of TNF mediated pathways regulates inflammatory cell death signaling in healthy and diseased tissues. Front. Cell Dev. Biol., v.8, p.365, 2020.

FUNDING

This work was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil.

DATA AVAILABILITY STATEMENT

The research data are available upon request.

*

Corresponding author: silviaohubner@gmail.com

Editor-chefe:

Marcelo Resende de Souza

Editor-científico:

Antônio de Pinho Marques Jr.

Publication Dates

  • Publication in this collection
    28 Sept 2026
  • Date of issue
    2026

History

  • Received
    29 Sept 2025
  • Accepted
    04 Apr 2026
location_on
Universidade Federal de Minas Gerais, Escola de Veterinária Caixa Postal 567, 30123-970 Belo Horizonte MG - Brazil, Tel.: (55 31) 3409-2041, Tel.: (55 31) 3409-2042 - Belo Horizonte - MG - Brazil
E-mail: abmvz.artigo@gmail.com
rss_feed Stay informed of issues for this journal through your RSS reader
Go to top